News - Gastro-intestinals


Current filters:


Popular Filters

100 to 124 of 187 results

Study finds potential use of ustekinumab for Crohn's disease


Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results…

BiotechnologyGastro-intestinalsJanssenJohnson & JohnsonPharmaceuticalResearchStelara Injectionustekinumab

Unanimous FDA advisory panel backing for NPS Pharma's Gattex


The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee yesterday voted unanimously…

Gastro-intestinalsGattexNorth AmericaNPS PharmaceuticalsPharmaceuticalRegulationteduglutide

FDA posts briefing papers for review of NPS Pharma's Gattex for SBS


The USA Food and Drug Administration has posted briefing materials for the October 16 Gastrointestinal…

Gastro-intestinalsGattexNorth AmericaNPS PharmaceuticalsPharmaceuticalRegulation

Abbott's Humira gets FDA backing for new use


US health care major Abbott Laboratories (NYSE: ABT) says that the US Food and Drug Administration has…

Abbott LaboratoriesGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Uptake of biosimilars will see Remicade and Humira sales decline in 2017


The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP


The European Medicines Agency last Friday issued a batch of recommendations relating to marketing authorization…

AlmirallBayerConstellaEuropeEyleaGastro-intestinalsIronwood PharmaceuticalsNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Pharmaceutical majors unite in Japan to combat H. pylori


On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan


SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

Almirall gains rights for IBS drug linaclotide in Mexico


Spain's largest drugmaker Almirall (ALM. MC) says it has reached an agreement with USA-based Forest Laboratories…

AlmirallForest LaboratoriesGastro-intestinalsLicensinglinaclotidePharmaceuticalSouth America

US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis


When evaluating the most important attributes for emerging therapies for Crohn's disease (CD) and ulcerative…

BiotechnologyGastro-intestinalsHumiraMarkets & MarketingNorth AmericaRemicadeSimponi Injectionvedolizumab

FDA action on Salix' crofelemer delayed until 2013


There was disappointing news for Salix Pharmaceuticals (Nasdaq: SLXP) with the Food and Drug Administration…

crofelemerGastro-intestinalsNorth AmericaPharmaceuticalRegulationSalix Pharmaceuticals

Takeda's Revestive gets EU clearance for short bowel syndrome


Japan's largest drugmaker Takeda Pharmaceutical (TSE: 4502) and partner NPS Pharmaceuticals (Nasdaq:…

EuropeGastro-intestinalsNPS PharmaceuticalsPharmaceuticalRegulationRevestiveTakeda Pharmaceuticals

FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation


The US Food and Drug Administration last week approved Linzess (linaclotide), co-marketed by US drugmakers…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideLinzessNorth AmericaPharmaceuticalRegulation

Abbott's Humira cleared for Crohn's disease in EU


The European Commission has approved US health care major Abbott Laboratories' (NYSE: ABT) blockbuster…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

Abbott's Humira gains FDA panel backing for wider use


The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee yesterday voted by 15…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Pushing the IBS pipeline for promising therapies


Both the current filed status and Phase III pipeline for irritable bowel syndrome (IBS) are sparse. The…

Gastro-intestinalsMarkets & MarketingPharmaceuticalResearch

ICDR rules in favor of Glenmark over Crofelemer


Indian drugmaker Glenmark Pharmaceuticals saw its shares rise 2.3% to 415 rupees yesterday after the…

crofelemerGastro-intestinalsGlenmark PharmaceuticalsLegalNapo PharmaceuticalsPharmaceutical

Pfizer RA drug candidate tofacitinib shows promise in ulcerative colitis


Patients with moderately to severely active ulcerative colitis treated with drug behemoth Pfizer's (NYSE…


AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer


Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…


Salix and Alfa Wassermann expand rifaximin accord


USA-based Salix Pharmaceuticals (Nasdaq: SLXP) and Italy's Alfa Wassermann have entered into an exclusive…

Alfa WassermannGastro-intestinalsLicensingPharmaceuticalRespiratory and PulmonaryrifaximinSalix Pharmaceuticals

Latest role for aspirin may be in protecting against Barrett's esophagus


Along with its original use as a pain killer, and its protection against heart attack, the ubiquitous…


100 to 124 of 187 results

Company Spotlight



Back to top